Astria TherapeuticsATXS
Market Cap: $697M
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 59
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 101 [Q1] → 99 (-2) [Q2]
2.03% less ownership
Funds ownership: 105.38% [Q1] → 103.36% (-2.03%) [Q2]
37% less capital invested
Capital invested by funds: $814M [Q1] → $516M (-$297M) [Q2]
63% less call options, than puts
Call options by funds: $215K | Put options by funds: $577K
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wedbush Laura Chico 50% 1-year accuracy 37 / 74 met price target | 78%upside $22 | Outperform Reiterated | 13 Aug 2024 |
Oppenheimer Hartaj Singh 35% 1-year accuracy 8 / 23 met price target | 111%upside $26 | Outperform Maintained | 13 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 30%upside $16 | Buy Reiterated | 13 Aug 2024 |
TD Cowen Stacy Ku 0% 1-year accuracy 0 / 1 met price target | 183%upside $35 | Buy Initiated | 29 Jul 2024 |
Financial journalist opinion
Based on 4 articles about ATXS published over the past 30 days